自本世纪初至七十年代,充血性心衰(CHF)的治疗几无进展。虽洋地黄继续被公认为治疗CHF的唯一有效心脏收缩增强剂,但显效和中毒量的比率窄;许多病人虽使用治疗量,CHF仍难控制,形成所谓“顽固性心衰”。近年来,由于对CHF病生理的进一步了解,治疗上出现了两类重要进展:1.血管扩张剂和2.非洋地黄类心脏收缩增强剂的应用。本文复习后者的研究和应用进展。 There have been few advances in the treatment of congestive heart failure (CHF) since the early 2000s and the 1970s. Although digitalis continues to be recognized as the only potent cardiac contractile enhancer for the treatment of CHF, the ratio between effective and toxic doses is narrow; in many patients, CHF is still difficult to control and forms the so-called “refractory heart failure.” In recent years, due to further understanding of the physiology of CHF, there have been two major advances in treatment: vasodilators and 2. The use of non-digitalis systolic agents. This article reviews the latter’s research and application progress.